Low-Dose Naltrexone (LDN).

Compounding and integrative practice have long paired low-dose naltrexone with alpha-lipoic acid, and the pairing is described in case-level clinical writing rather than in controlled work. The two act on completely separate targets: naltrexone occupies opioid receptors, alpha-lipoic acid works as a redox-active dithiol cofactor. Nothing about the combination has been measured head to head, so read it as a co-use convention with a mechanistic rationale, not a demonstrated additive effect.

Naltrexone's non-opioid action includes antagonism at toll-like receptor 4 on glial cells, and curcuminoids are also described as dampening TLR4-driven signalling in cell work. The overlap is at the same node, which is why formulators put them together. No human study has tested the pair. Read it as mechanistic rather than clinical.

N-acetylcysteine feeds the cystine-glutamate antiporter and supports glutathione synthesis in glial cells, the same cell population where low-dose naltrexone's TLR4 antagonism is thought to act. The two arrive at glial signalling from different directions. There is no combination trial, and the rationale is entirely mechanistic.

Low-dose naltrexone is conventionally taken at night, and vivid dreaming or disturbed sleep is the most commonly reported early complaint, which is why melatonin appears alongside it in practice. Melatonin acts at MT1 and MT2 receptors and has no interaction with opioid receptor occupancy. The pairing is a timing convention rather than a measured interaction.

Naltrexone undergoes extensive first-pass hepatic metabolism, principally reduction to 6-beta-naltrexol by dihydrodiol dehydrogenase, followed by glucuronidation. Silymarin flavonolignans are themselves heavily glucuronidated and sulfated. Competition at conjugation enzymes is plausible on established biochemistry but has not been measured for this pair, so any effect on exposure is unquantified.

Boswellic acids act on 5-lipoxygenase and leukotriene formation, a different arm of eicosanoid signalling from the glial receptor route attributed to low-dose naltrexone. Products aimed at joint comfort and mobility often carry both. No trial has separated the contributions, so the row records a formulation pattern with distinct mechanisms rather than a tested synergy.

Vitamin D3 is routinely part of the same protocol sheets that carry low-dose naltrexone, since the vitamin D receptor is expressed on most immune cell lineages and status is easy to measure. That is a co-use convention, not a pharmacological interaction: cholecalciferol and naltrexone share no absorption route, no metabolising enzyme and no receptor. Nothing here is an outcome claim.